drugset / Trial / NCT00708422

Effects of Travatan Z and Xalatan on Ocular Surface Health

NCT00708422

Phase 4 Completed 231 enrolled Alcon Research
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.

Timeline

Start
2008-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Topical
Subject Travoprost Other / unclassified 0.004 % Topical